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Cytotoxic cutaneous T-cell lymphomas (CTCLs)
are a heterogeneous group of lymphoproliferative
disorders characterized by localization of atypical T
cells in the skin that often express CD56 and
cytotoxic granules. CTCLs exhibit a wide range of
clinical and histopathologic features but tend to
be aggressive.1 Often diagnosis relies heavily on
immunohistochemistry.We report a case of cytotoxic
CTCL with a unique immunophenotype.neous T-cell lymphoma
TCR: T-cell receptorCASE REPORT
A 69-year-old white man had annular plaques on
sun-exposed areas of his body. Two lesional
biopsies found a lymphocytic infiltrate lacking atypia
andmonoclonality. Diffuse dermal mucin deposition
was observed, consistent with tumid lupus. The
patient was treated with topical fluocinonide cream
and hydroxychloroquine, 400 mg daily, later
increased to 600 mg, with significant improvement.
Three months later skin lesions of a different
morphology developed: nodules on his upper
arms and thighs that enlarged and involuted
spontaneously. Lesional biopsies of the right arm
and right leg found an atypical population of CD31,
CD561, and CD4/CD8 double negative (DN)
lymphocytes of medium to large size, consistent
with CTCL. Hydroxychloroquine was discontinued,
and the patient’s nodules resolved.
When the patient presented to us, he had a 1-cm
ill-defined indurated nodule on his back, an
arcuate lesion on his upper abdomen, and several
erythematous patches in sun-exposed areas. Athe Departments of Dermatology,a Pathology,b and Radia-
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rmatology, The University of Texas MD Anderson Cancerbiopsy of the nodule found a predominantly CD31
infiltrate with a normal CD4:CD8 ratio, preserved
CD7 expression, and negative CD30 and CD56
expression. There was a mild increase in dermal
mucin, consistent with the original diagnosis of
tumid lupus. A repeat biopsy 2 weeks later showed
only perifollicular granulomatous inflammation.
Bone marrow biopsy, peripheral blood flow cytom-
etry, and positron emission tomography/computed
tomography (PET/CT) scan were within normal
limits. At follow-up 6 months later, the patient
remained free of all lesions suggestive of lymphoma.
Two years later, the patient returned with new
violaceous annular plaques on the left popliteal
fossa, right forearm, and the left thigh (Fig 1, A).
He was treated unsuccessfully for 2 months with
0.05% fluocinonide cream. A biopsy of the left
popliteal fossa found an atypical dermal lymphocytic
infiltrate with focal epidermotropism. The cells wereCenter, Pickens Tower, FCT11.6097, 1515 Holcombe Boulevard,
Houston, TX 77030. E-mail: cwang4@mdanderson.org.
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Fig 1. Recurrent cutaneous T-cell lymphoma. A, Indurated violaceous plaques with arcuate
morphology. B, Complete response to radiation.
Fig 2. A, Histopathologic findings. A dense infiltrate of atypical lymphocytes in the dermis and
with focal epidermotropism. B, The atypical cells are diffusely positive for CD56. C, The
atypical infiltrate expresses bF1. (A, Hematoxylin-eosin stain; original magnification:34; B and
C, Immunohistochemistry; original magnification: 310.)
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258 Wang et alCD31, CD561, CD30, and CD4/CD8 DN by immu-
nohistochemistry (Fig 2, A-C ). TIA1 and granzyme B
were positive, and Epstein-Barr viruseencoded
small RNAs (EBER) by in situ hybridization were
negative. T-cell receptor (TCR) gene rearrangement
studies showed bF11 and TCRg. PET/CT and
peripheral blood flow cytometry were again
unremarkable. The lesions responded to 8 Gy of
local electron beam radiation (Fig 1, B). Five months
later, the patient had new lesions on his forearms and
left thigh. The patient was treated again with local
electron beam, with near-complete response to
therapy.DISCUSSION
CTCLs have a wide spectrum of clinical
presentations, making lesional biopsy tantamount
to diagnosis. Classification of CTCLs follows World
Health Organization (WHO)eEuropean Organi-
zation for Research and Treatment of Cancer
(EORTC) guidelines using clinical, histologic, immu-
nophenotypic, and genetic features.2 However,
diagnoses are often made based on histopathology
alone.
We report an unusual case of CTCL with an
unusual CD31 cytotoxic immunophenotype that is
not easily classified under the current WHO-EORTC
Table I. Differential diagnosis for cytotoxic lymphomas
Our patient Extranodal NK/TCL SPCTL PCGDTCL
Anaplastic large
cell lymphoma
CD81 aggressive
epidermotropic CTCL
Behavior Indolent Aggressive Indolent Aggressive Indolent Aggressive
Immunostaining CD31 CD3 CD31 CD21 CD31 CD31
CD4 CD4 CD31 CD41 CD4
CD8 CD8/1 CD4 CD4 CD8/1 CD81
CD561 CD561 (strong) CD81 CD8/1 CD56/1
CD56/1 CD56/1 CD301
CD30/1
CD45RO1 CD45RO1 CD45RO
CD45RA CD45RA CD45RO1 CD45RA1
Perforin1 Perforin1 Perforin1
Granzyme B1 Granzyme B1 Granzyme B1 Granzyme B1
TIA11 TIA11 Granzyme B1 TIA11 TIA11 TIA11
TIA11
TCR gene TCR g/d No TCR rearrangement TCR g/d TCR g/d1 Variable Variable
TCR bF11 TCR bF11 TCR bF1
EBV status EBER EBER1 EBER EBER EBER/1 EBER
Histology Atypical dermal
infiltrate of medium
to large cells with
epidermotropism
Dense diffuse
infiltrates; small
to large cells with
pleomorphic nuclei
and pale cytoplasm
Variably sized
pleomorphic
infiltrating fat
lobules and
resemble lobular
panniculitis;
frequently with
fat necrosis &
foamy histiocytes
Epidermotropic (pagetoid)
vs dermal (diffuse or
nodular) 6 subcutaneous
component.
Infiltrate composed of medium
to large cells w/irregular
chromatin-dense or vesicular
nuclei, angioinvasion, &
necrosis common
Nodular cohesive
infiltrates of
large pleomorphic,
anaplastic, or
immunoblastic
tumor cells ([75%
must be CD301)
Bandlike
epidermotropic
infiltrate of small-
medium or medium-
large lymphocytes
w/pleomorphic
chromatin-dense
nuclei. Numerous
apoptotic necrotic
keratinocytes and
spongiosis
Clinical
presentation
Localized deep red
annular plaques
Necrotic and ulcerated
nodules or tumors
Subcutaneous
plaques or
nodules
Generalized often necrotic or
ulcerated papules, plaques,
or nodules; mucosal and
organic involvement common
Solitary nodules
or tumors
Widespread plaques
and nodules, often
with hemorrhage
and ulceration
Data from Willemze et al2-4 and Santucci et al.8
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260 Wang et alguidelines.2,3 Several other cytotoxic CTCL entities
were considered in the differential diagnosis,
including subcutaneous panniculitic cutaneous
T-cell lymphoma (SPTCL), primary cutaneous
gamma-delta T-cell lymphoma (PCGD-TCL), extra-
nodal natural killer (NK)/TCL, cutaneous anaplastic
large cell lymphoma, and CD81 aggressive
epidermotropic CTCL (Table I). Although our
patient’s CTCL had a CD4/CD8 DN, CD561
phenotype, and cytotoxic molecule expression
(TIA1, perforin, granzyme B), features suggestive
of PCGD-TCL and extranodal NK/T-cell lymphoma,
the expression of the bF1 TCR precludes
classification as a PCGD-TCL. bF1 positivity is seen
in SPCTLs, which can also express CD56 and
cytotoxic molecules and typically exhibits an
indolent course, but the patient’s lack of subcutane-
ous involvement is inconsistent with such.2,4
The negative EBER challenged the diagnosis of
extranodal NK/T-cell lymphoma.2,3 Primary
cutaneous anaplastic large cell lymphoma is rarely
CD561, but its diagnosis requires more than 75%
CD30 positivity, a feature this case consistently
lacked.2 It is important to note that the EBER staining
method detects Epstein-Barr virus RNA by in situ
hybridization. False-negative readings result from
RNA degradation in the tissue and can be prevented
with controls such as the polyT probe.5 We routinely
use positive and negative controls for our in situ
hybridization for EBER.
Only rarely have CD31, CD4/CD8 DN CTCLs
been reported and most possess the g/d TCR unlike
our patient’s variant, which is bF11/g l, indicating
an a/b phenotype.6,7 In a study of 48 cases of
cytotoxic CTCLs, 5 cases of CD4/CD8 DN peripheral
T-cell lymphoma (PTCL) unspecified were reported.
Two of these cases were bF11. It is unknown
whether CD56 was positive in these cases. It was
noted that a subset of unspecified PTCLs are
indolent.8 There is an uncommon variant of
epidermotropic mycosis fungoides that is CD4/CD8
DN and bF11/g and portends an indolent course.6
Otherwise, most CD4/CD8 DN lymphomas exhibit
an aggressive course that is often refractory to
treatment.7 CD56 is a nonspecific marker of NK cellsand is not only seen in NK lymphomas but also in
PCGD-TCLs, another aggressive disease.2,3 The
concomitant expression of CD56 and a/b TCR with
cytotoxic granule proteins has not been previously
described.
The patient’s initial diagnosis with tumid lupus
and lymphomatous lesions that spontaneously
resolved is also unusual. Given that early-stage
CTCL can mimic benign conditions, the patient’s
presentations likely represent one clinical entity.
Under WHO-EORTC guidelines, this patient’s
disease is best classified as a peripheral T-cell
lymphoma, not otherwise specified (PTCL-NOS).2,3
Because PTCL-NOS can be systemic, complete
lymphoma staging was done to screen for blood,
lymph node, and bone marrow involvement using
peripheral blood flow cytometry, PET-CT, and bone
marrow biopsy. There is no standard treatment
for PTCL-NOS. The patient was treated with skin-
directed electron beam therapy because he has stage
I disease limited to the skin.
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